Olaparib was already shown to be effective in breast cancer treatment [17-21, 23, 24], but now we also demonstrate the prophylactic effect of systemic PARP-inhibition in Brca1-associated breast cancer. The gene discussed is BRCA1; the disease is breast carcinoma.